BrioHealth Solutions has announced a significant milestone with the 100th patient enrolled in the INNOVATE Trial of its BrioVAD System, a next-generation Left Ventricular Assist Device designed for advanced heart failure care. The BrioVAD System is engineered to improve blood flow, enhance patient comfort, reduce complications, and address the unmet clinical needs of patients whose hearts can no longer pump effectively. By focusing on patient safety and long-term outcomes, the device aims to minimize adverse events and give patients more time and improved quality of life.
Health Technology Insights: Nemluvio Shows Rapid Itch Relief and Sleep Benefits
“Reaching the 100th enrollment in the INNOVATE Trial is an extraordinary achievement for our team and, most importantly, for the patients we serve,” said Chen Chen, Ph.D., CEO of BrioHealth Solutions. “This milestone highlights the dedication of our clinical partners and demonstrates the potential of the BrioVAD® System to expand treatment options and transform care for those living with advanced heart failure.”
Health Technology Insights: Form Health Offers Clear, Predictable GLP-1 Coverage for Employers
The INNOVATE Trial, launched in late 2024, is a nationwide study involving leading cardiac centers to evaluate the safety and effectiveness of the BrioVAD System. The trial is focused on developing more durable and reliable mechanical heart pumps that can enhance both survival rates and quality of life for patients with advanced heart failure. Each implantation contributes valuable data toward understanding the full potential of the device and refining future treatment strategies.
“Every successful implantation brings us closer to unlocking the full benefits of the BrioVAD® System and expanding treatment possibilities for patients,” said Francis D. Pagani, M.D., Ph.D., Otto Gago, M.D., Professor of Cardiac Surgery at the University of Michigan Medical School and National Principal Investigator of the INNOVATE Trial. “The progress we have seen so far is promising, and we remain committed to advancing the science that will define the next generation of therapies for heart failure patients.”
The INNOVATE Trial continues to enroll participants while collecting crucial data to guide the development of future heart failure treatments. BrioHealth remains focused on creating innovative solutions that improve patient outcomes, reduce complications, and provide patients with the opportunity to enjoy longer, healthier lives.
Health Technology Insights: FDA Approves Exdensur (Depemokimab) for Severe Asthma
To participate in our interviews, please write to our HealthTech Media Room at info@intentamplify.com
